Developing Oral LT3 Therapy for Heart Failure -... - Thyroid UK

Thyroid UK

140,948 members166,081 posts

Developing Oral LT3 Therapy for Heart Failure - HFpEF (DOT3HF-HFpEF)

helvella profile image
helvellaAdministrator
8 Replies

Just looking for something else, and noticed this ongoing study.

Developing Oral LT3 Therapy for Heart Failure - HFpEF (DOT3HF-HFpEF)

Study Overview

Brief Summary:

Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with preserved ejection fraction (HFpEF) and low triiodothyronine (T3) syndrome by conducting a randomized, double-blind, placebo-controlled cross-over study with a two-week washout period between treatments.

Detailed Description:

The overall goal is to determine the safety, feasibility, and preliminary efficacy of administering oral LT3 therapy in the study population of participants with Heart Failure with preserved ejection fraction (HFpEF). Each treatment period will be approximately 8 weeks in duration, with weekly titration of study drug for 4 weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to the other arm (placebo or drug). LT3 will be titrated to T3 levels.

beta.clinicaltrials.gov/stu...

Thought it might be interesting in the first place for those warned off liothyronine due to its impact on the heart! The study is not complete and reported, hence only of passing interest.

Written by
helvella profile image
helvella
Administrator
To view profiles and participate in discussions please or .
Read more about...
8 Replies
humanbean profile image
humanbean

I think this would give many UK endocrinologists a fit.

helvella profile image
helvellaAdministrator in reply tohumanbean

Or a heart attack?

humanbean profile image
humanbean in reply tohelvella

Ooh, that would been a better ending to my comment! 😁

tattybogle profile image
tattybogle

"LT3 will be titrated to T3 levels"

What .... ignore the TSH ?

..... they can't do that .. the sky will fall in, the patients heads will explode , and/ or they'll get so hooked on feeling 'energetic' that they'll need to be escorted to London and booked into Jim's T3 rehab clinic.

helvella profile image
helvellaAdministrator in reply totattybogle

I wasn't clear whether that was FT3 or TT3 - which is why I ignored it!

humanbean profile image
humanbean

Each treatment period will be approximately 8 weeks in duration, with weekly titration of study drug for 4 weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to the other arm (placebo or drug).

I've seen a few references to "washing out" thyroid hormones in research involving thyroid disease. It always gives me a horrible feeling as I imagine myself being in the shoes of those going through it. It would be a nightmare!

Based on the exclusion criteria none of the participants will have treated hypothyroidism or hyperthyroidism, although we all know that diagnosis of various thyroid conditions can be delayed for years, so some people with untreated thyroid disease might creep in whether the researchers want this or not.

I wonder what they mean by a "maintenance dose" of T3 "for four weeks" since theoretically their exclusion criteria says they won't be using people with thyroid disease. So what would a maintenance dose consist of?

helvella profile image
helvellaAdministrator in reply tohumanbean

Maybe email the listed contact?

tattybogle profile image
tattybogle in reply tohumanbean

entry criteria was 'low T3 syndrome' so... assuming that means 'T3 below range' ? .... presumably maintenance dose is 'one that keeps T3 in range' .. don't know if that's TT3 or fT3 .

Not what you're looking for?

You may also like...

EXTENDED ABSORPTION OF LIOTHYRONINE FROM POLY-ZINC-LIOTHYRONINE (PZL): RESULTS FROM A PHASE 1, STUDY IN HUMANS

Very small, very early trial. At least none of the 12 healthy volunteers seemed have an awful time....
helvella profile image
Administrator

RANDOMIZED CONTROLLED TRIAL EVALUATING THE CARDIO-METABOLIC EFFECTS OF LEVOTHYROXINE AND LIOTHYRONINE

An interesting preprint paper re liothyronine. (Apologies for SHOUTING - using capitals - but I...
helvella profile image
Administrator

Very encouraging performance by a chemical analogue of T3 in stabilising FT3 by those who take T3

This is a hot preprint which describes the use of an analogue of T3 that stabilises T3 levels in...
diogenes profile image
Remembering

A prime example of bad misleading research

A little bit of scientific comment and analysis to discriminate plausible papers from rubbish. In...
diogenes profile image
Remembering

Moderation team

See all
RedApple profile image
RedAppleAdministrator
PurpleNails profile image
PurpleNailsAdministrator
SlowDragon profile image
SlowDragonAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.